Program
Azacitidine
Also written as “azacitidine”, “Azacitidine (AZA)” and “Eganelisib in combination with azacitidine”.
Its studies are mostly in Leukemia, Myeloid, Acute · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Hematologic Neoplasms · Lymphoma, T-Cell, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 161 open or running | phase 4since Sep 13, 2010 | Oct 31, 2003 | none ahead |
| Takeda | 30 open or running | phase 3since Aug 30, 2017 | May 28, 2009 | none ahead |
| Hikma Pharmaceuticals | 21 open or running | phase 1since Mar 11, 2024 | Mar 11, 2024 | none ahead |
| bioniche-pharma-usa-llc | 10 open or running | phase 1since Jun 25, 2010 | Jun 25, 2010 | none ahead |
| Johnson & Johnson | 10 open or running | phase 2since Feb 7, 2020 | Feb 7, 2020 | none ahead |
| Merck | 10 open or running | phase 2since Nov 24, 2014 | Nov 24, 2014 | none ahead |
| nanexa-ab | 10 open or running | phase 1since May 11, 2021 | May 11, 2021 | none ahead |
| Nob Hill Therapeutics | 11 open or running | phase 2since Sep 10, 2026 | Sep 10, 2026 | Jul 13, 2029phase 2 · NCT07864584 |
| Sarah Cannon Research Institute | 10 open or running | phase 2since Oct 4, 2006 | Oct 4, 2006 | none ahead |
Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd, Hoffmann-La Roche, roche-genentech, takeda-development-center-americas-inc and argenx.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Oct 31, 2003.
- May 14, 2012Phase 2 study in Myelodysplastic SyndromesBristol-Myers Squibb · NCT01599325 · 72 enrolled · China
- Nov 24, 2014Merck's first study: phase 2 study in Leukemia, Myeloid, AcuteNew to MerckMerck · NCT02303782
- Apr 14, 2015Phase 2 study in Myelodysplastic SyndromesBristol-Myers Squibb · NCT02447666 · 28 enrolled · Austria, Belgium, Czechia and more
- May 19, 2015Phase 2 study in Leukemia, Myeloid, AcuteBristol-Myers Squibb · NCT02450877 · 7 enrolled · Denmark, Germany, Netherlands
- Feb 5, 2016Phase 2 study in Leukemia, Myeloid, AcuteBristol-Myers Squibb · NCT02677922 · 130 enrolled · United States, Australia, Belgium and more
- May 20, 2016Phase 1 study in Leukemia, Myeloid, AcuteTakeda · NCT02782468 · 23 enrolled · Japan, Korea, Republic of, Taiwan
- Aug 30, 2017Phase 3 study in Myelodysplastic SyndromesTakeda · NCT03268954 · 454 enrolled · United States, Australia, Belgium and more
- Oct 9, 2018Phase 3 study in Lymphoma, T-CellBristol-Myers Squibb · NCT03703375 · 93 enrolled · Japan
- Feb 7, 2020Johnson & Johnson's first study: phase 2 study in Myelodysplastic SyndromesNew to Johnson & JohnsonJohnson & Johnson · NCT04264806 · Australia, Brazil, France and more
- Feb 2, 2021Phase 1 study in Leukemia, MyeloidBristol-Myers Squibb · NCT04748848 · 1 enrolled · United States, Belgium, France and more
- May 11, 2021nanexa-ab's first study: phase 1 study in Myelodysplastic SyndromesNew to nanexa-abnanexa-ab · NCT05048498 · 2 enrolled · Sweden
- Mar 11, 2024Hikma Pharmaceuticals's first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT06326697 · 32 enrolled · Saudi Arabia
- Aug 22, 2024No phase study in Leukemia, Myeloid, AcuteHikma Pharmaceuticals · NCT06572982 · 20 enrolled · United Arab Emirates
- Sep 10, 2026Nob Hill Therapeutics's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Nob Hill TherapeuticsNob Hill Therapeutics · NCT07864584 · 100 planned · United States
Ahead
- Jul 13, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNob Hill Therapeutics · NCT07864584
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07864584Carcinoma, Non-Small-Cell Lung · United States | 2 | Not yet recruiting | Nob Hill Therapeutics | Jul 13, 2029 | 100 |
| NCT06572982Leukemia, Myeloid, Acute · United Arab Emirates | – | Active, not recruiting | Hikma Pharmaceuticals | May 2026 | 20 |
| NCT06326697Leukemia, Myeloid, Acute · Saudi Arabia | 1 | Completed | Hikma Pharmaceuticals | Aug 17, 2025 | 32 |
| NCT05048498Myelodysplastic Syndromes · Sweden | 1 | Completed | nanexa-ab | Feb 10, 2022 | 2 |
| NCT04748848Leukemia, Myeloid · United States, Belgium, France and more | 1 | Terminated | Bristol-Myers Squibb | Mar 9, 2022 | 1 |
| NCT04264806Myelodysplastic Syndromes · Australia, Brazil, France and more | 2 | Withdrawn | Johnson & Johnson | Apr 19, 2022 | 0 |
| NCT03703375Lymphoma, T-Cell · Japan | 3 | Completed | Bristol-Myers Squibb | Feb 10, 2021 | 93 |
| NCT03268954Myelodysplastic Syndromes · United States, Australia, Belgium and more | 3 | Completed | Takeda | May 28, 2021 | 454 |
| NCT02782468Leukemia, Myeloid, Acute · Japan, Korea, Republic of, Taiwan | 1 | Completed | Takeda | Jan 25, 2022 | 23 |
| NCT02677922Leukemia, Myeloid, Acute · United States, Australia, Belgium and more | 2 | Active, not recruiting | Bristol-Myers Squibb | Aug 2, 2018 | 130 |
| NCT02450877Leukemia, Myeloid, Acute · Denmark, Germany, Netherlands | 2 | Completed | Bristol-Myers Squibb | Oct 10, 2018 | 7 |
| NCT02447666Myelodysplastic Syndromes · Austria, Belgium, Czechia and more | 2 | Completed | Bristol-Myers Squibb | Feb 28, 2018 | 28 |
| NCT02303782Leukemia, Myeloid, Acute | 2 | Withdrawn | Merck | Mar 2016 | 0 |
| NCT01599325Myelodysplastic Syndromes · China | 2 | Completed | Bristol-Myers Squibb | Jan 29, 2015 | 72 |
| NCT01358734Leukemia, Myeloid, Acute · United States, Canada | 2 | Completed | Bristol-Myers Squibb | May 19, 2015 | 88 |
| NCT01201811Myelodysplastic Syndromes · Taiwan | 4 | Completed | Bristol-Myers Squibb | May 1, 2013 | 44 |
| NCT01186939Myelodysplastic Syndromes · Australia, Bulgaria, France and more | 3 | Completed | Bristol-Myers Squibb | Sep 1, 2009 | 40 |
| NCT01152346Myelodysplastic Syndromes · United States, France | 1 | Completed | bioniche-pharma-usa-llc | Dec 2012 | 19 |
| NCT01074047Leukemia, Myeloid, Acute · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Jan 22, 2014 | 488 |
| NCT00911066Leukemia, Myeloid, Acute · United States | 1 | Completed | Takeda | Aug 2013 | 72 |
| NCT00761722Leukemia, Myeloid, Acute · United States | 1 | Completed | Bristol-Myers Squibb | Apr 6, 2016 | 31 |
| NCT00666497Leukemia, Myeloid, Acute · United States, Canada, United Kingdom | 2 | Terminated | Bristol-Myers Squibb | Apr 2009 | 6 |
| NCT00652626Multiple Myeloma · United States | 1 | Completed | Bristol-Myers Squibb | Jul 1, 2012 | 31 |
| NCT00528983Myelodysplastic Syndromes · United States | 1 | Completed | Bristol-Myers Squibb | Jul 31, 2013 | 133 |
| NCT00384839Prostatic Neoplasms · United States | 2 | Completed | Sarah Cannon Research Institute | Nov 2009 | 36 |
| NCT00102687Myelodysplastic Syndromes · United States | 2 | Completed | Bristol-Myers Squibb | Aug 1, 2008 | 151 |
| NCT00071799Myelodysplastic Syndromes · United States, Australia, Bulgaria and more | 3 | Completed | Bristol-Myers Squibb | Jul 1, 2007 | 358 |
How it is read
Names in the registry
- “Azacitidine”, 36 entries
- “azacitidine”, 8 entries
- “Azacitidine (AZA)”, 2 entries
- “Eganelisib in combination with azacitidine”, 1 entry
- “NHT102”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 30 studies
- Myelodysplastic Syndromes, 18 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Hematologic Neoplasms, 1 study
- Lymphoma, T-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.